Jonathan Brotchie
Dr Jonathan Brotchie is a co-Founder, Director and President of Atuka
Inc (2011-present). Dr Brotchie has more than 25 years' experience in
Parkinson's disease research, managing teams in both academia and in
commercial environments that have identified and validated several drug
targets for PD. He has lead translational research that has supported
the assessment of efficacy of more than 25 drug candidates in non-human
primate models of PD and the advancement of 8 drug candidates to
clinical studies. Dr Brotchie has also been named inventor/ co-inventor
on 13 families of patents related to novel therapeutics for movement
disorders. In addition to Atuka Inc, he has founded, and held senior
management positions in, two other successful PD-focussed CROs, Atuka
Ltd (Founder and Director, 2003-present) and Motac (CEO and Director,
1999-2002).
He has held academic positions at University Health Network, Toronto (2002-present) and University of Manchester (1991-2002). He gained his PhD from University of Manchester, UK for research on the role of the subthalamic nucleus in the generation of symptoms of Parkinson's disease. Dr Brotchie has published more than 100 peer-reviewed academic papers, has sat on the Editorial Board of the journals Movement Disorders and Synapse, he has also consulted for more than 30 biopharmaceutical companies as well as for members for the financial community. He works closely with several Parkinson's charities, as advisor or reviewer of proposals for funding, including Michael J Fox Foundation, Cure Parkinson's Trust and Parkinson Society Canada.
He has held academic positions at University Health Network, Toronto (2002-present) and University of Manchester (1991-2002). He gained his PhD from University of Manchester, UK for research on the role of the subthalamic nucleus in the generation of symptoms of Parkinson's disease. Dr Brotchie has published more than 100 peer-reviewed academic papers, has sat on the Editorial Board of the journals Movement Disorders and Synapse, he has also consulted for more than 30 biopharmaceutical companies as well as for members for the financial community. He works closely with several Parkinson's charities, as advisor or reviewer of proposals for funding, including Michael J Fox Foundation, Cure Parkinson's Trust and Parkinson Society Canada.